|1.||Ha, Belinda: 9 articles (03/2015 - 11/2006)|
|2.||Tierney, Camlin: 7 articles (03/2015 - 12/2009)|
|3.||Sax, Paul E: 7 articles (09/2014 - 12/2009)|
|4.||Daar, Eric S: 7 articles (09/2014 - 12/2009)|
|5.||McComsey, Grace A: 6 articles (03/2015 - 06/2011)|
|6.||Kitch, Douglas: 5 articles (03/2015 - 06/2011)|
|7.||Melbourne, Kathleen: 4 articles (09/2014 - 06/2011)|
|8.||Jahed, Nasreen C: 4 articles (07/2012 - 12/2009)|
|9.||DeJesus, Edwin: 4 articles (11/2006 - 05/2006)|
|10.||Calza, Leonardo: 3 articles (01/2016 - 04/2008)|
|1.||Kidney Diseases (Kidney Disease)
12/01/2013 - "We studied 40 virologically controlled Caucasian patients on stable treatment (median >4 years) with tenofovir/emtricitabine + nevirapine (n = 20) or abacavir/lamivudine + nevirapine (n = 20), and no history of kidney disease, high blood pressure or diabetes. "
03/01/2014 - "Changes in renal function significantly improved (or declined less) with abacavir/lamivudine treatment compared with tenofovir/emtricitabine using the Cockcroft-Gault formula (P = .016) and 2009 Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI; P = .030) and 2012 CKD-EPI cystatin C-creatinine (P = .025). "
09/01/2009 - "Switching from a protease inhibitor- and thymidine analogue-based antiretroviral regimen to atazanavir/ritonavir plus abacavir/lamivudine or tenofovir/emtricitabine proved effective in the management of hyperlipidemia, without significant differences in lipid-lowering effect, virologic efficacy, and safety profile between these regimens."
09/01/2009 - "Randomized, open-label, prospective clinical trial assessing efficacy and safety on hyperlipidemia of a switching from a regimen including one protease inhibitor and one thymidine analogue to atazanavir/ritonavir plus abacavir/lamivudine or tenofovir/emtricitabine. "
09/01/2009 - "Adult HIV-infected patients on their first antiretroviral therapy (of at least 48-week duration), including one protease inhibitor and zidovudine or stavudine, with stable immunovirologic features, and having diagnosis of persisting hyperlipidemia, were randomized to replace current treatment with atazanavir/ritonavir plus abacavir/lamivudine (arm A) or tenofovir/emtricitabine (arm B), and were followed for 48 weeks. "
|3.||Acquired Immunodeficiency Syndrome (AIDS)
01/01/2015 - "Combination dolutegravir-abacavir-lamivudine in the management of HIV/AIDS: clinical utility and patient considerations."
07/01/2010 - "Abacavir + lamivudine had similar efficacy to its comparators (OR 0.81, 95% CI 0.8-1.1), but more AIDS-defining events (OR 3.22, 95% CI 1.24, 8.40). "
01/01/2013 - "Co-formulated abacavir-lamivudine-zidovudine for initial treatment of HIV infection and AIDS."
01/01/2009 - "A combination drug of abacavir-lamivudine-zidovudine (Trizivir) for treating HIV infection and AIDS."
03/01/2015 - "We examined BMD data at the lumbar spine and hip from AIDS Clinical Trials Group (ACTG) A5224s and ASSERT and randomized treatment-naive studies comparing TDF/emtricitabine versus abacavir/lamivudine (with efavirenz or atazanavir/ritonavir). "
12/15/2015 - "Brief Report: Dolutegravir Plus Abacavir/Lamivudine for the Treatment of HIV-1 Infection in Antiretroviral Therapy-Naive Patients: Week 96 and Week 144 Results From the SINGLE Randomized Clinical Trial."
05/01/2014 - "Dolutegravir will likely play a major role in the management of patients with HIV-1 infection, and will be aided when coformulation with abacavir/lamivudine as a single pill, once-daily regimen is available. "
11/07/2013 - "Dolutegravir plus abacavir-lamivudine for the treatment of HIV-1 infection."
04/15/2006 - "A one-tablet, once-daily abacavir/lamivudine fixed-dose combination (FDC) has been recently approved to treat HIV-1 infection. "
12/01/2005 - "Fixed dose combination abacavir/lamivudine in the treatment of HIV-1 infection."
|5.||HIV Infections (HIV Infection)
09/01/2009 - "To assess the potency, efficacy and toxicity of abacavir/lamivudine (ABC/3TC) versus tenfovir/emcitrabine (TDF/FTC) with efavirenz (EFV) in naive patients with HIV infection a prospective observational study was carried out to evaluate immunovirological parameters every three months and metabolic parameters every six months. "
01/01/2013 - "Using the GRADE approach, we rated the overall quality of the evidence on the relative effects of co-formulated abacavir-lamivudine-zidovudine for initial treatment of HIV infection as moderate. "
01/01/2013 - "To evaluate the effects of any fixed-dose combination of three NRTIs (co-formulated abacavir-lamivudine-zidovudine) for initial treatment of HIV infection. "
12/01/2009 - "A French Caucasian man aged 39 with HIV infection was treated with abacavir/lamivudine and ritonavir/lopinavir. "
01/01/2009 - "The aim of this review was to evaluate the effects of Trizivir, a fixed-dose combination of three NRTIs (abacavir-lamivudine-zidovudine) for initial treatment of HIV infection. "
|5.||Protease Inhibitors (Protease Inhibitor)
|2.||Highly Active Antiretroviral Therapy (HAART)